

27 May 2022

Dear 

Re: Official Information Act

I am responding on behalf of Taranaki District Health Board (DHB) to your OIA request of 29 April 2022. You have requested the following information:

Can the DHB please advise how many courses of the following Covid-19 treatments have been dispensed to both inpatients and outpatients between January 1 and April 28:

- *Baricitinib (Olumiant)*
- *Casirivimab with imdevimab (Ronapreve)*
- *Nirmatrelvir and Ritonavir (Paxlovid)*
- *Remdesivir (Veklury)*
- *Tocilizumab (Actemra)*

Please find the information requested in the *Appendix*.

I trust this information answers your OIA request.

Kind regards



Katy Sheffield
Deputy Chief Operating Officer

Enc.

Appendix

Medication	Number of Entire Courses
Baricitinib (Olumiant)	Nil
Casirivimab with imdevimab (Ronapreve)	Nil
Nirmatrelvir and Ritonavir (Paxlovid)	1 course
Remdesivir (Veklury)	5 courses
Tocilizumab (Actemra)	5 courses

Please note:

- The information provided is for the period of 1 January – 28 April 2022.
- The above information relates only to inpatient dispensing; Taranaki DHB is unable to report on outpatient treatment, as this medication is dispensed by community pharmacies.
- Number of Entire Courses:
 - Some courses have been dispensed in 2 lots, i.e. half a course then remainder when more stock arrived. These 2 lots have been counted as 1 course.
 - These numbers may also not have been for the same patient due to time frame requested.